Fisons
Executive Summary
Six top-ranking execs visit FDA June 22 to discuss the company's "future direction" with Deputy Commissioner for Operations Jane Henney, MD, CDER Director Carl Peck, MD, General Counsel Margaret Porter, and others. Fisons execs attending included Pharmaceutical Chairman and company CEO Cedric Scroggs. The British-based company's Opticrom cromolyn sodium anti-allergy eye drops and Imferon injectable iron continue to be unavailable in the U.S. due to regulatory problems at Fisons' Holmes Chapel, U.K. facility. FDA made its fourth inspection visit in two years to Holmes Chapel in April to review Opticrom manufacturing practices ("The Pink Sheet" May 11, T&G-13).